Literature DB >> 19686534

Selecting healthy volunteers in specific populations: a retrospective analysis of clinical and laboratory screening.

Clarisse Roux1, Hugues Chevassus, Anne Farret, Françoise Costa, Pierre Petit, Florence Galtier.   

Abstract

Healthy volunteers must undergo a medical examination before enrollment in a clinical trial. An increasing number of trials include specific populations designed to match the target populations of the drugs tested. Our study aimed at evaluating which investigations are the most appropriate in different sub-populations of healthy volunteers. Data from 350 healthy volunteers who attended our Research Center from 1997 to 2004 were retrospectively analysed. Volunteers were distributed into five sub-populations: young men, senior men, overweight men, young women, postmenopausal women. The screening procedure comprised a review of medical history, physical examination, electrocardiogram and laboratory tests. Ineligibility criteria were classified as non-medical causes, protocol specific medical causes and non-specific medical causes. A total of 148 subjects (42%) were not-eligible, mainly because of non-specific medical causes (111 subjects), including abnormal medical history (34.5% of all ineligibilities). Blood pressure abnormalities were frequent in all sub-populations except young women. Electrocardiographic abnormalities led to ineligibility of only five overweight men and one menopausal woman. Abnormal laboratory tests accounted for 19.6% of ineligibilities. In senior subjects and overweight men, serologies, liver function tests and lipid profile contributed importantly to the selection process. Low red cells count was the most frequent laboratory abnormality in young women. Erythrocyte sedimentation rate, phosphocalcic metabolism and standard clotting tests led to frequent insignificant and non-contributive abnormalities. Our study confirms that a complete review of medical history is essential and determines the major part of ineligibilities. Complementary laboratory tests are always needed and may be adjusted to the population considered.

Entities:  

Mesh:

Year:  2009        PMID: 19686534     DOI: 10.1111/j.1472-8206.2009.00727.x

Source DB:  PubMed          Journal:  Fundam Clin Pharmacol        ISSN: 0767-3981            Impact factor:   2.748


  2 in total

1.  Data driven evaluation of healthy volunteer characteristics at screening for phase I clinical trials to inform on study design and optimize screening processes.

Authors:  Annemie Deiteren; Erwin Coenen; Sabine Lenders; Peter Verwilst; Erik Mannaert; Freya Rasschaert
Journal:  Clin Transl Sci       Date:  2021-08-11       Impact factor: 4.689

Review 2.  A Systematic Review and Pooled Analysis of Select Safety Parameters Among Normal Healthy Volunteers Taking Placebo in Phase 1 Clinical Trials.

Authors:  Tina C Young; Subasree Srinivasan; Marion L Vetter; Venkat Sethuraman; Zubin Bhagwagar; Ricardo Zwirtes; Premkumar Narasimhan; Tilda Chuang; Brendan J Smyth
Journal:  J Clin Pharmacol       Date:  2017-05-16       Impact factor: 3.126

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.